BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37227518)

  • 21. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
    Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
    Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria.
    Pengpis N; Prueksrisakul T; Chanswangphuwana C
    Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e167-e173. PubMed ID: 36173715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durometry for the assessment of skin disease in systemic sclerosis.
    Kissin EY; Schiller AM; Gelbard RB; Anderson JJ; Falanga V; Simms RW; Korn JH; Merkel PA
    Arthritis Rheum; 2006 Aug; 55(4):603-9. PubMed ID: 16874783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous Chronic Graft Versus Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in Children: A Retrospective Study.
    Shreberk-Hassidim R; Neumark M; Greenberger S; Goldstein G; Hassidim A; Dukler Y; Maly A; Stepensky P; Molho-Pessach V
    Acta Derm Venereol; 2018 Feb; 98(2):206-211. PubMed ID: 29057425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring Biomechanical Properties Using a Noninvasive Myoton Device for Lymphedema Detection and Tracking: A Pilot Study.
    Glassman GE; Dellalana L; Tkaczyk ER; Esteve IM; Huang JY; Cronin A; Patrinely JR; Etemad S; Assi PE; Ridner S; Forte AJ; Kassis SA; Perdikis G
    Eplasty; 2022; 22():e54. PubMed ID: 36448050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.
    Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L
    Ann Hematol; 2019 Aug; 98(8):1867-1875. PubMed ID: 30993415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a durometer to assess skin hardness.
    Falanga V; Bucalo B
    J Am Acad Dermatol; 1993 Jul; 29(1):47-51. PubMed ID: 8315077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
    Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
    J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
    [No Abstract]   [Full Text] [Related]  

  • 30. Genetic risk factors for sclerotic graft-versus-host disease.
    Inamoto Y; Martin PJ; Flowers ME; Lee SJ; Carpenter PA; Warren EH; Geraghty DE; Lee N; Boeckh MJ; Storer BE; Levine DM; Fan W; Zhao LP; Hansen JA
    Blood; 2016 Sep; 128(11):1516-24. PubMed ID: 27313329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
    Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances and research progress in biomarkers for chronic graft versus host disease.
    Ji R; Li Y; Huang R; Xiong J; Wang X; Zhang X
    Crit Rev Oncol Hematol; 2023 Jun; 186():103993. PubMed ID: 37061073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myofibroblasts generated in culture from sclerotic skin lesions of a patient with extensive chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation are of recipient origin.
    Goussetis E; Spiropoulos A; Theodosaki M; Stefanaki K; Petrakou E; Graphakos S
    Stem Cells Dev; 2010 Sep; 19(9):1285-7. PubMed ID: 20001597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
    Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
    Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
    Merkel EC; Mitchell SA; Lee SJ
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic graft-versus-host disease in pediatric patients: Differences and challenges.
    Haroun E; Agrawal K; Leibovitch J; Kassab J; Zoghbi M; Dutta D; Lim SH
    Blood Rev; 2023 Jul; 60():101054. PubMed ID: 36805299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines.
    Kim M; Renert-Yuval Y; Stepensky P; Even-Or E; Zaidman I; Fachler T; Neumark M; Zamir M; NandyMazumdar M; Gour D; Facheris P; Carroll B; Liu Y; Yu Ekey ML; Andrews E; Meariman M; Angelov M; Bose S; Estrada YD; Molho-Pessach V; Guttman-Yassky E
    J Invest Dermatol; 2024 Mar; 144(3):563-572.e9. PubMed ID: 37742913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
    Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
    Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.